June 10, 2015
This video from the National Institute of Allergy and Infectious Diseases (NIAID) looks at current efforts to improve hepatitis C (HCV) treatment, including curing hard-to-treat HCV, particularly in patients who are coinfected with HCV and HIV. In the District of Columbia, where an estimated 15,000 people are living with HCV, researchers and patients discuss the difficulties of managing and treating HCV.
Many hepatitis C patients do not complete the standard treatments because these therapies are complex, lengthy and can cause severe side effects, according to the video. "If you don't do anything, a lot of these patients will develop liver failure and die," says Shyamasundaran Kottilil, M.D., Ph.D., in an on-screen interview.
However, the video highlights the high cure rates of available HCV drugs, as well as current clinical trials focusing on newer treatments with shorter duration and fewer side effects. Study participants in these trials also receive other care, including support to quit drinking and using other drugs.
Watch the video:
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2015 Remedy Health Media, LLC. All rights reserved.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|Let's Advance the Conversation Among Black Women on HIV and PrEP|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|